Tumor cells often hijack normal physiological processes to support their growth, exploiting proteins that are in charge of essential cell functions. It is therefore important to block the activity of ...

Pfizer announced that a late-stage trial in lung cancer for a Seagen-derived ADC, sigvotatug vedotin, has failed. Phase I ...

Water-soluble polymers conjugated to proteins and anticancer drugs are in routine clinical use and clinical development as both single agents and components of combination therapy. This is ...

Spotlighting Innovation in Novel Targeting Formats & Payloads to Enhance Delivery, Overcome Payload Resistance and Expand Therapeutic Reach Novel conjugates have become one of the most competitive and ...

The hottest cancer technology from the turn of the century is finally getting its glow-up moment, as clinical trials continue to show that antibody-drug conjugates (ADCs) perform better than standard ...

Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study Antibody-drug conjugates (ADCs) are ...

Two major studies are looking at moving sacituzumab govitecan earlier for metastatic triple-negative breast cancer.

Antibody-drug conjugates are a new kind of targeted treatment for multiple myeloma. They deliver powerful cancer-killing drugs straight to myeloma cells, and they help your own immune system attack ...

Driving Innovation in Discovery and Chemistry, Validating Clinical Proof-of Concept and Streamlining CMC of Conjugates with Novel Payloads and Formats Traditional ADCs have seen significant success in ...

Cancer treatments often struggle with balancing efficacy and side effects. A new study scientists offers a promising solution using antibody-peptide inhibitor conjugates to target specific cell types ...